Investigation into intratumoral heterogeneity (ITH) of the epigenome is in a formative stage.
The patterns of tumor evolution inferred from epigenetic ITH and genetic ITH are remarkably …

Epigenetic modifications, like histone acetylation, are essential for regulating gene
expression within cells. Cancer cells acquire pathological epigenetic modifications resulting …

An increasingly recognized resistance mechanism to androgen receptor (AR)-directed
therapy in prostate cancer involves epithelial plasticity, in which tumor cells demonstrate low …

A major hurdle in the study of rare tumors is a lack of existing preclinical models.
Neuroendocrine prostate cancer is an uncommon and aggressive histologic variant of …

Loss of androgen receptor (AR) signaling dependence occurs in approximately 15%–20%
of advanced treatment-resistant prostate cancers, and this may manifest clinically as …

Background Although aberrant DNA methylation has been observed previously in acute
lymphoblastic leukemia (ALL), the patterns of differential methylation have not been …

Despite advances in the development of highly effective androgen receptor (AR)-directed
therapies for the treatment of men with advanced prostate cancer, acquired resistance to …

Castration-resistant prostate cancer (CRPC) is a heterogeneous disease associated with
phenotypic subtypes that drive therapy response and outcome differences. Histologic …

Clear cell renal cell carcinoma (ccRCC) is characterized by accumulation of neutral lipids
and adipogenic transdifferentiation. We assessed adipokine expression in ccRCC and …

The identification of biomarkers indicating the level of aggressiveness of prostate cancer
(PCa) will address the urgent clinical need to minimize the general overtreatment of patients …